156 related articles for article (PubMed ID: 38451960)
21. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Deng Y; Tong Y; Deng Y; Zou L; Li S; Chen H
J Am Heart Assoc; 2019 Jul; 8(14):e012540. PubMed ID: 31310583
[TBL] [Abstract][Full Text] [Related]
22. Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists.
Di Nisio M; Ageno W; Rutjes AW; Pap AF; Büller HR
Thromb Haemost; 2016 Jan; 115(2):424-32. PubMed ID: 26511068
[TBL] [Abstract][Full Text] [Related]
23. Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial.
De Vriese AS; Caluwé R; Van Der Meersch H; De Boeck K; De Bacquer D
J Am Soc Nephrol; 2021 Jun; 32(6):1474-1483. PubMed ID: 33753537
[TBL] [Abstract][Full Text] [Related]
24. Rivaroxaban: an oral factor Xa inhibitor.
Thomas TF; Ganetsky V; Spinler SA
Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
[TBL] [Abstract][Full Text] [Related]
25. Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation.
Connolly SJ; Karthikeyan G; Ntsekhe M; Haileamlak A; El Sayed A; El Ghamrawy A; Damasceno A; Avezum A; Dans AML; Gitura B; Hu D; Kamanzi ER; Maklady F; Fana G; Gonzalez-Hermosillo JA; Musuku J; Kazmi K; Zühlke L; Gondwe L; Ma C; Paniagua M; Ogah OS; Molefe-Baikai OJ; Lwabi P; Chillo P; Sharma SK; Cabral TTJ; Tarhuni WM; Benz A; van Eikels M; Krol A; Pattath D; Balasubramanian K; Rangarajan S; Ramasundarahettige C; Mayosi B; Yusuf S;
N Engl J Med; 2022 Sep; 387(11):978-988. PubMed ID: 36036525
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
[TBL] [Abstract][Full Text] [Related]
27. Non-vitamin K antagonist oral anticoagulants (NOACs) post-percutaneous coronary intervention: a network meta-analysis.
Al Said S; Alabed S; Kaier K; Tan AR; Bode C; Meerpohl JJ; Duerschmied D
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD013252. PubMed ID: 31858590
[TBL] [Abstract][Full Text] [Related]
28. Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer.
Lee JH; Oh YM; Lee SD; Lee JS
J Korean Med Sci; 2019 Jun; 34(21):e160. PubMed ID: 31144482
[TBL] [Abstract][Full Text] [Related]
29. A retrospective study of real-world effectiveness and safety of rivaroxaban in patients with non-valvular atrial fibrillation and venous thromboembolism in Saudi Arabia.
Alosaimi HM; Alqahtani S; Balkhi B; Alqahtani M; Alzamil F; Alhossan A; Alqahtany FS; Alharbi AA; Alqahtani NA; Albackr H; Elgohary G; Algahtani FH
PeerJ; 2022; 10():e13974. PubMed ID: 36105646
[TBL] [Abstract][Full Text] [Related]
30. Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data.
Dawwas GK; Leonard CE; Lewis JD; Cuker A
Ann Intern Med; 2022 Jan; 175(1):20-28. PubMed ID: 34871048
[TBL] [Abstract][Full Text] [Related]
31. Heavy menstrual bleeding in women treated with rivaroxaban and vitamin K antagonists and the risk of recurrent venous thromboembolism.
Bryk AH; Piróg M; Plens K; Undas A
Vascul Pharmacol; 2016 Dec; 87():242-247. PubMed ID: 27865826
[TBL] [Abstract][Full Text] [Related]
32. Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis.
de Jong LA; Gout-Zwart JJ; van den Bosch M; Koops M; Postma MJ
J Med Econ; 2019 Apr; 22(4):306-318. PubMed ID: 30614320
[TBL] [Abstract][Full Text] [Related]
33. The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: A network meta-analysis.
Oh HJ; Ryu KH; Park BJ; Yoon BH
Medicine (Baltimore); 2021 Mar; 100(11):e25216. PubMed ID: 33726018
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
[TBL] [Abstract][Full Text] [Related]
35. Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice.
Vimalesvaran K; Dockrill SJ; Gorog DA
Vasc Health Risk Manag; 2018; 14():13-21. PubMed ID: 29391805
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data.
Costa OS; Beyer-Westendorf J; Ashton V; Milentijevic D; Moore KT; Bunz TJ; Coleman CI
J Thromb Thrombolysis; 2021 Feb; 51(2):349-358. PubMed ID: 32588288
[TBL] [Abstract][Full Text] [Related]
37. Updated Renal Dosage Recommendations for Rivaroxaban in Patients Experiencing or at Risk of Thromboembolic Disease.
Volkl AA; Moore KT; Haskell L; Barnathan ES
Am J Cardiovasc Drugs; 2023 May; 23(3):247-255. PubMed ID: 37115488
[TBL] [Abstract][Full Text] [Related]
38. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism.
Chen DY; Tseng CN; Hsieh MJ; Lan WC; Chuang CK; Pang ST; Chen SW; Chen TH; Chang SH; Hsieh IC; Chu PH; Wen MS; Chen JS; Chang JW; See LC; Huang WK
JAMA Netw Open; 2021 Feb; 4(2):e2036304. PubMed ID: 33533929
[TBL] [Abstract][Full Text] [Related]
39. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Beyer-Westendorf J; Ageno W
Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism.
Coleman CI; Turpie AGG; Bunz TJ; Beyer-Westendorf J
Am J Med; 2018 Aug; 131(8):933-938.e1. PubMed ID: 29526541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
